Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Bempedoic Acid Gains CV Risk Reduction Indication

Todd Neale

March 22, 2024

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Grants Stroke Prevention Indication to Ticagrelor

Shelley Wood

November 06, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Triple Therapy Polypill for High Blood Pressure

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Bempedoic Acid Gains CV Risk Reduction Indication

FDA Approves Colchicine for Decreasing CV Events

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

British Medical Groups Express Concern About Inclisiran Rollout

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Grants Stroke Prevention Indication to Ticagrelor

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Gives Rivaroxaban Another VTE-Related Indication

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Betrixaban Approved for Prevention of VTE

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content